Fuzzy Panda Research has hit AirSculpt Technologies Inc AIRS, a company focused on providing body contouring (liposuction) procedures in the U.S.
The report highlights a series of practices that raise serious concerns about the safety and credibility of the plastic surgery company.
Founder Dr. Aaron Rollins has marketed the company’s fat removal/transfer procedure as a safe alternative, comparing the risk to getting a tooth pulled.
However, Fuzzy report notes that the investigation has uncovered a different reality.
The investigation revealed instances where the AirSculpt procedure was linked to the “cause of death” of a 37-year-old mother, contradicting the company’s claims of a flawless safety record.
Patients have come forward with harrowing experiences, describing being “burned from the inside out” and facing serious scarring, maiming, or disfigurement.
The suspect doctors employed by AirSculpt, with questionable credentials and some operating with revoked State Medical Licenses, are equally concerning.
The report highlights that over 65% of AirSculpt’s recent doctors are not board-certified, and 20% have faced disciplinary action or serious malpractice lawsuits.
The company’s questionable practices extend beyond medical credentials, involving false advertising.
AirSculpt has been caught posing employees as satisfied patients in testimonials and paying influencers for positive reviews without disclosing compensation.
Even before-and-after images, a key marketing strategy, were found to be consistently digitally altered, claims the report.
The investigation found that AirSculpt’s claimed patent for its technology does not exist, and the company uses a commonly available FDA-approved device owned by another company.
The safety of patients is also a significant concern, as former employees disclosed that the company systemically flaunts health codes and safety standards, potentially exposing patients to HIV or Hepatitis by reusing disposable surgical devices.
Furthermore, questions surround Dr. Aaron Rollins’ credentials, including being denied a Washington State medical license and facing sanctions from the California State Medical Board for misleading advertising.
Price Action: AIRS shares are down 20.50% at $4.93 on the last check Friday.
Photo by Andrey_Popov via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.